Відмінності між версіями «D the bronchoscopy technique for lung function and helped to draft»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | J Med. 2014;370(22):2071?two. | + | 3Department of [http://www.medchemexpress.com/AZD0865.html Linaprazan biological activity] Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. A phase three trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. three. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. 4. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(two):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. Int J Exp Pathol. 2002;83(3):111?. doi:10.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One particular. 2013;eight(four):e59348. doi:ten.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] choices for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?two. doi:ten.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models a number of options of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors study and approved the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection at the end from the animal experiments. None in the authors had precise funding for this study. C. Samuel is supported by a National Overall health Medical Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Overall health Medical Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author details 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:10.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. |
Версія за 10:07, 3 лютого 2018
3Department of Linaprazan biological activity Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. A phase three trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. three. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. 4. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(two):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. Int J Exp Pathol. 2002;83(3):111?. doi:10.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One particular. 2013;eight(four):e59348. doi:ten.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment title= jir.2011.0103 choices for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?two. doi:ten.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models a number of options of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors study and approved the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection at the end from the animal experiments. None in the authors had precise funding for this study. C. Samuel is supported by a National Overall health Medical Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Overall health Medical Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author details 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:10.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R.
